Andrew Davies, MRCP, PhD from University of Southampton, Southampton, UK discusses diffuse large B-Cell lymphoma (DLBCL). A study conducted in Denmark looked at patients who had received complete remission (CR) or complete remission unconfirmed (CRU) compared with a matched population. It was shown that patients under 50 had the same overall survival (OS) as the normal population. In patients over 50 there is still gap between DLBCL patients and the normal populations OS. Dr Davies further discusses a randomized Phase III trial examining the effect of early intensification of rituximab (ISRCTN82286322). The results showed that increasing rituximab dose during the first four cycles does not influence metabolic CR rate and progression- free survival (PFS). Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.